NEWTOWN, Pa., Oct. 19, 2015 /PRNewswire/ -- BioClinica®, Inc., a specialty clinical trials technology services provider, today announced the roll out of a new eClinical CRO Partner Alliance program, accelerating adoption of industry-leading eHealth solutions by CROs. The decision to redesign the CRO partner channel comes in response to growing demand for a premier eClinical technology platform that enables CROs and sponsors to conduct studies in an efficient and accelerated manner.
"We listened to our eClinical CRO customers, sponsors and the wider community to understand business pain-points, as well as the overall experience of working with technology product providers," said Mukhtar Ahmed, BioClinica's eClinical business segment president. "Based on feedback from senior clinical development, outsourcing and IT executives, it was evident a completely different partnering approach and philosophy was desired." Ahmed explained, "Among their top priorities are CRO autonomy and product self-service capability, as well as access to a wealth of knowledge and best practices. They want this within a true partnership − one with strategic business alignment, collaboration and accountability for service delivery and product quality."
To address this need, BioClinica's eClinical CRO Partner Alliance is flexible and built around each partner's unique needs and business model. BioClinica Director of CRO Business Development, Jason Attanucci said, "Our CRO partners receive flexible licensing, preferred pricing and incentives along with service and quality assurance benefits, which ultimately help them reach sponsor customers previously inaccessible."
Dedicated CRO relationship managers work closely with each partner to create a tailored eHealth solution offering. Partners may leverage certification and services in the BioClinica platform or individual solutions to achieve unique financial benefits in areas including:
"The breadth of services and technology available through our eClinical CRO Partner Alliance has never been seen before in this industry," Attanucci said. Partners are able to leverage BioClinica's extensive knowledge gained in providing study management, risk-based monitoring, data capture, randomization and trial supply management technology and supporting services for thousands of clinical trials globally. "We've already seen tremendous uptake in our Partner Alliance from CROs around the world, and we will begin announcing new members in coming weeks."
In addition to BioClinica's world-class data, regulatory, reporting and analytics technology, CRO partners can tap into unique product innovation found within the eHealth App xChange™. The App xChange enables access to a growing list of consumer applications, such as electronic health records, patient diaries, adherence, safety utilities, questionnaires, eTMF, and other patient-centric apps in a secure and scalable way through BioClinica's regulatory compliant eHealth Cloud™ architecture.
To kick off the new CRO Partner Alliance, BioClinica invites prospective partners to stop by its exhibit at the Partnerships in Clinical Trials conference in Hamburg, Germany on November 18 and 19 to learn about partnering opportunities and see product demonstrations. BioClinica's Global Product Development Senior Vice President, Andrew Masters, will speak on an expert panel on RBM best practices and lessons learned.
Organizations interested in joining BioClinica's CRO Partner Alliance can learn more online where a Contact Us request may be submitted. Follow BioClinica on the Trial Blazer blog and on Twitter at http://twitter.com/bioclinica.
About BioClinica, Inc.
BioClinica is a specialty clinical trials technology services provider that improves the development of new medical therapies by delivering expertise and technologies that enhance clinical research data and analytics, worldwide. The company offers industry-leading medical imaging services, enterprise eClinical technologies, patient recruitment and retention, clinical research centers and cardiovascular safety solutions that bring quality and efficiency to every phase of clinical development. BioClinica's experience spans three decades and includes thousands of studies in all therapeutic areas. The company serves more than 400 pharmaceutical, biotechnology, and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia. For more information, please visit www.bioclinica.com.
SOURCE BioClinica, Inc.